1.
Geissler K, Jäger E, Barna A, Sliwa T, Knöbl P, Schwarzinger I, Gisslinger H, Valent P. Is ruxolitinib a potentially useful drug in hematological malignancies with RAS pathway hyperactivation?. Haematologica [Internet]. 2016Nov.30 [cited 2026Nov.18];101(12):e492-e492. Available from: https://haematologica.org/article/view/7925